K-679
/ Kowa
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 18, 2026
Selective intratumoral distribution and post-T-DXd activity of K-679, an ultra-high-DAR EGFR-targeted antibody drug-loaded unimicelle conjugate (ADUC)
(AACR 2026)
- "We investigated whether the ADUC design of K-679 enables tumor-selective pharmacokinetics (PK), extensive intratumoral distribution, spatial pharmacodynamics, and activity following prior T-DXd treatment. K-679 versus a benchmark ADC (cetuximab‑DM1 ADC, cleavable disulfide linker, DAR ~4.5) was evaluated in head-to-head comparisons using EGFR-expressing CDX (HT-29, SK‑OV-3, SK-CO-1 [KRAS G13V]) evaluated at DM1-equivalent dosing. The ultra-high-DAR ADUC design of K-679 confers tumor-selective PK, extensive intratumoral distribution, concordant spatial pharmacodynamics, and activity after prior T-DXd. These data support clinical development for EGFR-expressing solid tumors with low/heterogeneous antigen density and post-T-DXd settings."
ADC • Oncology • Solid Tumor • CD31 • HER-2 • KRAS • PECAM1
June 23, 2025
Hepatocyte ApoJ accelerates injury-induced liver fibrosis by activation STAT3 through Ranbp2 mediated-SUMOylation.
(PubMed, Cell Mol Gastroenterol Hepatol)
- "ApoJ plays a pivotal role in accelerating the progression of liver fibrosis. Therapeutic strategies targeting the ApoJ/STAT3/RanBP2 axis may offer a novel approach for the prevention and treatment of fibrotic liver diseases."
Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • CLU • RANBP2 • STAT3 • TGFB1
March 26, 2025
K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs
(AACR 2025)
- "Using this platform, we developed K-679, which combines cetuximab with DM1-loaded unimicelles. Antigen-binding specificity and cellular internalization of K-679 were evaluated using surface plasmon resonance, flow cytometry, and fluorescence microscopy. Our findings establish K-679 as a promising therapeutic candidate for heterogeneous EGFR-expressing solid tumors, characterized by a more potent anti-tumor effect through an exceptionally high DAR, enhanced drug accumulation into tumors and significant bystander effect."
Oncology • Solid Tumor • EGFR
April 21, 2025
K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors
(PRNewswire)
- "Kowa Company...today announced an upcoming presentation of non-clinical data for K-679...The compound, developed using Kowa's proprietary micelle technology, has demonstrated superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25th-30th, 2025 in Chicago, Illinois."
Preclinical • Solid Tumor
1 to 4
Of
4
Go to page
1